160 related articles for article (PubMed ID: 18596397)
1. High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission.
Raef H; Alfadhli E; Al-Hajjaj A; Malabu UH; Al-Sobhi S; Rifai A; Al Nuaim A
Ann Saudi Med; 2008; 28(4):277-81. PubMed ID: 18596397
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents.
Negre Busó M; García Burillo A; Simó Perdigó M; Galofré Mora P; Boronat de Ferrater M; Cuberas Borrós G; Sábado Álvarez C; Castell Conesa J
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1431-1441. PubMed ID: 32877364
[TBL] [Abstract][Full Text] [Related]
3. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
4. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
6. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
8. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
9. Death from thyroid cancer of follicular cell origin.
Wu HS; Young MT; Ituarte PH; D'Avanzo A; Duh QY; Greenspan FS; Loh KC; Clark OH
J Am Coll Surg; 2000 Dec; 191(6):600-6. PubMed ID: 11129807
[TBL] [Abstract][Full Text] [Related]
10. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
11. Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.
Lang BH; Wong KP; Wan KY
Ann Surg Oncol; 2013 Feb; 20(2):653-9. PubMed ID: 22956067
[TBL] [Abstract][Full Text] [Related]
12. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer.
Wang C; Chen X; Wei X; Chen F; Wang Y; Shen Z
Asian J Surg; 2017 Jan; 40(1):55-60. PubMed ID: 27697309
[TBL] [Abstract][Full Text] [Related]
13. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
[TBL] [Abstract][Full Text] [Related]
14. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
15. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
17. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
18. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
19. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma.
Simon D; Goretzki PE; Witte J; Röher HD
World J Surg; 1996 Sep; 20(7):860-6; discussion 866. PubMed ID: 8678963
[TBL] [Abstract][Full Text] [Related]
20. Low Recurrence Rates in a Cohort of Differentiated Thyroid Carcinoma Patients: A Referral Center Experience.
Scheffel RS; Zanella AB; Antunes D; Dora JM; Maia AL
Thyroid; 2015 Aug; 25(8):883-9. PubMed ID: 26061907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]